O

Oncternal Therapeutics
D

ONCT

1.71600
USD
0.08
(4.63%)
Market Closed
Volume
516
EPS
0
Div Yield
0
P/E
-0
Market Cap
5,078,751
OverviewSignalsIdeasNews
Related Instruments
    C
    CLRB
    -0.10000
    (-4.65%)
    2.05000 USD
    C
    CYCC
    0.02000
    (1.22%)
    1.66000 USD
    S
    SLS
    0.08000
    (6.90%)
    1.24000 USD
    T
    TNXP
    0.00960
    (1.92%)
    0.51050 USD
    V
    VRME
    0.03000
    (2.78%)
    1.11000 USD
    Z
    ZOM
    -0.00010
    (-0.07%)
    0.14950 USD
News

Title: Oncternal Therapeutics

Sector: Healthcare
Industry: Biotechnology
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.